213 related articles for article (PubMed ID: 24628831)
1. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular risk in patients with polycystic ovary syndrome.
Karbek B; Ozbek M; Karakose M; Topaloglu O; Bozkurt NC; Cakır E; Aslan MS; Delibasi T
J Ovarian Res; 2014 Mar; 7():31. PubMed ID: 24628831
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
Li X; Lin JF
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
[TBL] [Abstract][Full Text] [Related]
4. Subclinical atherosclerosis and hyperandrogenemia are independent risk factors for increased epicardial fat thickness in patients with PCOS and idiopathic hirsutism.
Cakir E; Doğan M; Topaloglu O; Ozbek M; Cakal E; Vural MG; Yeter E; Delibasi T
Atherosclerosis; 2013 Jan; 226(1):291-5. PubMed ID: 23206979
[TBL] [Abstract][Full Text] [Related]
5. Studies of cardiovascular risk factors in polycystic ovary syndrome patients combined with subclinical hypothyroidism.
Pei YJ; Wang AM; Zhao Y; Yan L; Li M; White RE; Han GC
Gynecol Endocrinol; 2014 Aug; 30(8):553-6. PubMed ID: 24884959
[TBL] [Abstract][Full Text] [Related]
6. Obese adolescents with polycystic ovarian syndrome have elevated cardiovascular disease risk markers.
Patel SS; Truong U; King M; Ferland A; Moreau KL; Dorosz J; Hokanson JE; Wang H; Kinney GL; Maahs DM; Eckel RH; Nadeau KJ; Cree-Green M
Vasc Med; 2017 Apr; 22(2):85-95. PubMed ID: 28095749
[TBL] [Abstract][Full Text] [Related]
7. Is copeptin a new potential biomarker of insulin resistance in polycystic ovary syndrome?
Widecka J; Ozegowska K; Banaszewska B; Kazienko A; Safranow K; Branecka-Wozniak D; Pawelczyk L; Kurzawa R
Ginekol Pol; 2019; 90(3):115-121. PubMed ID: 30949999
[TBL] [Abstract][Full Text] [Related]
8. Heart type fatty acid binding protein response and subsequent development of atherosclerosis in insulin resistant polycystic ovary syndrome patients.
Cakir E; Ozbek M; Sahin M; Cakal E; Gungunes A; Ginis Z; Demirci T; Delibasi T
J Ovarian Res; 2012 Dec; 5(1):45. PubMed ID: 23249450
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance and cardiovascular risk factors in women with PCOS who have normal glucose tolerance test.
Yildir IC; Kutluturk F; Tasliyurt T; Yelken BM; Acu B; Beyhan M; Erkorkmaz U; Yilmaz A
Gynecol Endocrinol; 2013 Feb; 29(2):148-51. PubMed ID: 23127112
[TBL] [Abstract][Full Text] [Related]
10. Circulating insulin-like peptide 5 levels and its association with metabolic and hormonal parameters in women with polycystic ovary syndrome.
Bicer M; Alan M; Alarslan P; Guler A; Kocabas GU; Imamoglu C; Aksit M; Bozkaya G; Isil AM; Baloglu A; Aslanipoiur B; Calan M
J Endocrinol Invest; 2019 Mar; 42(3):303-312. PubMed ID: 29956214
[TBL] [Abstract][Full Text] [Related]
11. Does cardiovascular risk vary according to the criteria for a diagnosis of polycystic ovary syndrome?
Ramoglu S; Yoldemir T; Atasayan K; Yavuz DG
J Obstet Gynaecol Res; 2017 Dec; 43(12):1848-1854. PubMed ID: 28892255
[TBL] [Abstract][Full Text] [Related]
12. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome.
Vryonidou A; Papatheodorou A; Tavridou A; Terzi T; Loi V; Vatalas IA; Batakis N; Phenekos C; Dionyssiou-Asteriou A
J Clin Endocrinol Metab; 2005 May; 90(5):2740-6. PubMed ID: 15741256
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic factors rather than vitamin D deficiency are related to insulin resistance in lean women with polycystic ovary syndrome.
Sahin S; Eroglu M; Selcuk S; Turkgeldi L; Kozali S; Davutoglu S; Muhcu M
Eur Rev Med Pharmacol Sci; 2014 Oct; 18(19):2851-6. PubMed ID: 25339479
[TBL] [Abstract][Full Text] [Related]
14. Echocardiographic evaluation of diastolic functions in patients with polycystic ovary syndrome: A comperative study of diastolic functions in sub-phenotypes of polycystic ovary syndrome.
Yildirim E; Karabulut O; Yuksel UC; Celik M; Bugan B; Gokoglan Y; Ulubay M; Gungor M; Koklu M
Cardiol J; 2017; 24(4):364-373. PubMed ID: 28353313
[TBL] [Abstract][Full Text] [Related]
15. Plasma selenium levels in Turkish women with polycystic ovary syndrome.
Coskun A; Arikan T; Kilinc M; Arikan DC; Ekerbiçer HÇ
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):183-6. PubMed ID: 23490536
[TBL] [Abstract][Full Text] [Related]
16. Association of insulin resistance with lipid profile, metabolic syndrome, and hormonal aberrations in overweight or obese women with polycystic ovary syndrome.
Ebrahimi-Mamaghani M; Saghafi-Asl M; Pirouzpanah S; Aliasgharzadeh A; Aliashrafi S; Rezayi N; Mehrzad-Sadaghiani M
J Health Popul Nutr; 2015 Mar; 33(1):157-67. PubMed ID: 25995732
[TBL] [Abstract][Full Text] [Related]
17. Increased adipsin is associated with carotid intima media thickness and metabolic disturbances in polycystic ovary syndrome.
Gursoy Calan O; Calan M; Yesil Senses P; Unal Kocabas G; Ozden E; Sari KR; Kocar M; Imamoglu C; Senses YM; Bozkaya G; Bilgir O
Clin Endocrinol (Oxf); 2016 Dec; 85(6):910-917. PubMed ID: 27434652
[TBL] [Abstract][Full Text] [Related]
18. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
[TBL] [Abstract][Full Text] [Related]
19. Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study.
Frøssing S; Nylander M; Aziz M; Skouby SO; Kistorp C; Faber J
Gynecol Endocrinol; 2017 Jan; 33(1):30-33. PubMed ID: 27424881
[TBL] [Abstract][Full Text] [Related]
20. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome.
Bicer M; Guler A; Unal Kocabas G; Imamoglu C; Baloglu A; Bilgir O; Yuksel A; Bozkaya G; Calan M
Endocr Res; 2017 May; 42(2):145-153. PubMed ID: 27911121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
